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is predominantly Caucasian, male (75%), younger (mean age 43),
and has a higher proportion of current and former drug users
(68%), than the Japanese cohort. We also had a lower prevalence
of cirrhosis (11%). These differences meant that some parts of the
decision tree were under populated. However, the tree was able
to identify a subgroup of patients who achieved a RVR, with nor-
mal platelets and a low viral load, representing 17.5% of the
cohort who had a 90% chance of achieving a SVR with standard
of care combination therapy. This level of SVR means it is much
more cost-effective to treat such patients with standard peginter-
feron and ribavirin than to add a protease inhibitor as ﬁrst line
therapy. Equally there is currently no evidence that the protease
inhibitors will improve the outcome in this patient group. We
congratulate Kurosaki and colleagues on an easy to use tool that
helps patients and physicians make decisions on starting therapy
and that with minor modiﬁcations may make the impact of the
introduction of protease inhibitors much more cost effective.
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identify patients with high probability of SVR among patients
who failed to achieve RVR
To the Editor:
We appreciate the interest of Dr. Wahed in our article recently
published in the Journal of Hepatology [1]. We were impressed
of their validation of our prediction model by substituting rapid
virological response (RVR) for IL28B genotype (modiﬁed model)
[2]. Wahed et al. showed that among patients with RVR, those
with high platelet counts (P140  109/L), and low HCV RNA
(<600,000 IU/ml)) had 90% chance of sustained virological
response (SVR). Their results conﬁrmed our ﬁnding that platelet
count and pretreatment HCV RNA level are predictors of SVR,
independently of early virological dynamics and showed that
combination of these factors improved the prediction accuracy.
However, according to their data, a modiﬁed model could not
identify patients who have high chance of SVR among those
who failed to achieve RVR.
In a study by Thompson et al. [3], RVR was correlated with
the IL28B genotype and was a strong predictor of SVR regard-
less of IL28B genotype. On the other hand, the major IL28B
genotype (CC at rs12979860) was associated with a higher rate
of SVR (among Caucasians, 66% (IL28B major genotype) vs. 31%
(IL28B minor hetero-genotype) and 24% (IL28B minor geno-
type)) among patients who failed to achieve RVR. There were
similar ﬁndings in our cohort, where patients with RVR had ahigh rate of SVR independent of IL28B genotype (97% for
IL28B major type vs. 100% for IL28B minor type) but among
non-RVR patients, the IL28B major genotype was associated
with signiﬁcantly higher rate of SVR (45% for IL28B major geno-
type vs. 12% for IL28B minor genotype). Collectively, IL28B
genotype has a signiﬁcant predictive power even after virolog-
ical response at week 4 of therapy was determined. This means
that RVR is associated with IL28B genotype but RVR could not
entirely replace IL28B genotype for the accurate prediction of
SVR. In order to assess if our model still has the power to pre-
dict SVR after virological response at week 4 of therapy was
determined, we modiﬁed our predictive model by adding RVR
as a ﬁrst splitting variable and applied the data of our cohort.
As a result, among patients who failed to achieve RVR in our
cohort, patients with IL28B major genotype who had (1) high
platelet counts (P140  109/L), and low HCV RNA
(<600,000 IU/ml) had 87% chance of SVR, (2) high platelet
counts (P140  109/L), and high HCV RNA (P600,000 IU/ml)
had 60% chance of SVR, and (3) low platelet counts
(<140  109/L), and more than 2 mutations in interferon sensi-
tivity determining region (ISDR) [4] had 69% chance of SVR
(Fig. 1). Patients who fall into these three groups constitute
39% of non-RVR patients. Thus, our predictive model could
determine patients with high probability of SVR even after
virological response at week 4 of therapy was determined.
We fully agree with Dr. Wahed that it is important to iden-
tify the patients who would be cured with current standard of1 vol. 55 j 1162–1168
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Fig. 1. Decision tree model incorporating RVR, IL28B genotype, and ISDR for the prediction of sustained virological response. The boxes indicate the factors used for
splitting. Pie charts indicate the rate of response for each group of patients after splitting. Dark blue charts indicate the rate of sustained virological response. RVR: rapid
virological response, ISDR: interferon sensitivity determining region.
JOURNAL OF HEPATOLOGYcare to reduce the implementation costs of new drugs such as
protease inhibitors and that RVR is the most reliable predictor
of SVR. In addition, we believe that determination of IL28B and
ISDR could further improve the prediction accuracy and that
predictive model incorporating RVR, IL28B genotype and ISDR
could be used not only for negative prediction but also for
positive prediction.Conﬂict of interest
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NKT cells in liver ﬁbrosis: Controversies or complexities
To the Editor:
We read with great interest a recent article in the Journal of Hepa-
tology by Ishikawa et al. investigating the role of CD1d-restricted
natural killer T (NKT) cells in thioacetamide (TAA)-induced liver
ﬁbrosis, by using CD1d knockout (KO) mice that are associated
with NKT cell deﬁciency [1]. First, the authors observed that
CD1d KO mice were resistant to TAA-induced liver inﬂammation,
damage, and hepatocyte apoptosis. Second, the authors observed
CD1d KO mice were resistant to TAA-induced liver ﬁbrosis, indi-
cating that NKT cells play an important role in promoting liver
ﬁbrogenesis in mice after chronic TAA treatment. The pro-ﬁbrotic
effects of NKT cells were also recently suggested by the data from
a murine model of HBV transgenic mice [2], primary biliary cir-
rhosis [3], nonalcoholic steatohepatitis (NASH), and patients with
NASH [4].
Recently, we identiﬁed the double sword face of invariant
NKT (iNKT, type I NKT) cells in liver ﬁbrogenesis in a model
of CCl4-induced liver injury [5]. On the one hand, iNKT-deﬁ-
cient mice had increased liver injury and ﬁbrosis, especially
in the early stage of CCl4-induced liver injury, suggesting that
natural activation of iNKT cells by endogenous lipid antigens
plays a protective role in preventing CCl4-induced liver injury
and ﬁbrosis. On the other hand, strong activation of iNKT cells
by a-galactosylceramide (a-GalCer) accelerated CCl4-induced
hepatocellular injury and subsequently enhanced ﬁbrosis. Our
ﬁndings clearly suggest a complex role of iNKT cells in liver
ﬁbrosis: inhibiting liver ﬁbrosis via the suppression of HSC
activation or indirectly promoting liver ﬁbrosis via enhancing
liver injury. We believe that the ﬁnal effect of iNKT cells on
liver ﬁbrosis is determined by the balance between the inhib-
itory and stimulatory effects as we discussed above, but may
also dependent on the real context of developing stage human
liver diseases or animal models used. In addition to iNKT (type
I NKT) cells, other subtypes of NKT cells including type II and
possible type III NKT cells also exist [6]. These different sub-
types of NKT cells exert many similar functions but may also
exert some opposing functions, which further complicates the
role of NKT cells in liver ﬁbrogenesis [6,7].
In the study by Ishikawa et al. [1], it appears that CD1d
restricted NKT cells play an important role in inducing liver
injury, which may contribute to the pro-ﬁbrotic effects of NKT
cells observed in the TAA-induced liver injury model. In the Sup-
plementary material, Ishikawa et al. [1], reported that CD1d KO
mice were also resistant to CCl4-induced acute liver injury; how-
ever, we found that CD1d KO mice had similar liver injury and
ﬁbrosis after chronic treatment with CCl4 (Park et al., unpublished
data). Further studies are required to clarify the complex role of
NKT cells in liver injury and ﬁbrosis.
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Reply to: ‘‘NKT cells in liver ﬁbrosis: Controversies or complexities’’
To the Editor:
Emerging attention has been paid to the role of natural killer T
(NKT) cells in a variety of liver diseases including nonalcoholic
steatohepatitis (NASH) [1]. The role of NKT cells in hepatic ﬁbro-
genesis, however, has been controversial [2–4]. In our latest man-
uscript entitled ‘‘CD1d-restricted natural killer T cells contribute
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